Indian court upholds grant of compulsory licence for Nexavar
This article was originally published in Scrip
Executive Summary
German multinational Bayer has failed to win any reprieve in the high profile case concerning its anticancer Nexavar (sorafenib tosylate) in India after the Bombay High Court upheld the grant of a compulsory license for the product to the domestic firm, Natco.